What is Triptorelin?
Triptorelin is a GnRH agonist used for hormone suppression in clinical settings. The featured breast-cancer analysis included several ways of achieving ovarian suppression.
Biological role or research focus
Ovarian suppression in hormone-sensitive cancer.
The randomized contrast was between endocrine-treatment strategies. Because ovarian suppression had multiple methods, the outcome difference cannot be attributed to triptorelin alone.
Role reference: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
- Class / identity
- GnRH receptor agonist
- Research focus
- Ovarian suppression in hormone-sensitive cancer
- Featured evidence
- Human randomized combination-treatment trials
- Source check
- October 4, 2026
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Quick answers
- Is Triptorelin FDA approved?
- Yes. Trelstar (NDA 020715, approved 2000) for advanced prostate cancer and Triptodur (NDA 208956, approved 2017) for central precocious puberty. Source ↗
- Is Triptorelin safe?
- Triptorelin is a GnRH agonist for advanced prostate cancer; hot flashes and sexual side effects are expected, and the label warns of early tumor flare plus heart, metabolic and seizure risks. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Triptorelin banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.1 Testosterone-stimulating peptides in males). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Combined TEXT / SOFT analysis (2014) | Human randomized combination-treatment trials | 4,690 premenopausal women with hormone-receptor-positive early breast cancer in the combined analysis. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized combination-treatment trials · 2014
Combined TEXT / SOFT analysis
How did two endocrine strategies compare when both included ovarian suppression?
- Population / model
- 4,690 premenopausal women with hormone-receptor-positive early breast cancer in the combined analysis.
- Study design
- Randomized comparison of exemestane plus ovarian suppression with tamoxifen plus ovarian suppression. Suppression was achieved using triptorelin, surgery, or irradiation.
- Main finding
- Five-year disease-free survival was 91.1% versus 87.3%: hazard ratio 0.72. Overall survival was not significantly different.
- Limits & context
- The randomized contrast was between endocrine-treatment strategies. Because ovarian suppression had multiple methods, the outcome difference cannot be attributed to triptorelin alone.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
44 registered studies name Triptorelin as an intervention among the 100 most recently updated of 298 search results; 19 are recruiting or under way, 1 has not started recruiting yet, 20 completed and 4 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 44 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Triptorelin. ↗
· 2012 · Review
Triptorelin embonate (6-month formulation). ↗
Drugs · 2010 Feb 12 · Journal Article, Review
An overview of treatments for endometriosis. ↗
JAMA · 2015 Jan 20 · Journal Article, Research Support, Non-U.S. Gov't, Review
Triptorelin for the treatment of endometriosis. ↗
Expert opinion on pharmacotherapy · 2014 Jun · Journal Article, Review
Risks & interactions
Triptorelin is a GnRH agonist for advanced prostate cancer; hot flashes and sexual side effects are expected, and the label warns of early tumor flare plus heart, metabolic and seizure risks.
Safety is established by FDA labeling for men with advanced prostate cancer. No formal drug interaction studies were done. It may impair fertility.
Take extra care with: Heart or blood pressure problemsDiabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeedingLiver problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Allergy to triptorelin, other GnRH agonists, GnRH or any ingredient
Interactions
- Drugs that raise prolactin: should not be used together, since high prolactin reduces pituitary GnRH receptors
- Drugs known to prolong the QT interval: androgen deprivation can itself prolong QT
Serious risks
- Temporary tumor flare early in treatment, which can cause spinal cord compression or urinary blockage
- Severe allergic reactions, including anaphylaxis and angioedema
- High blood sugar, diabetes, high lipids and fatty liver
- Heart attack, sudden cardiac death and stroke reported in men
- Seizures and severe skin reactions
- QT prolongation, and possible harm to an unborn baby
Common side effects
- hot flushes
- bone pain
- erectile dysfunction
- headache
- leg swelling
- leg pain
- testicular shrinkage
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Trelstar (triptorelin) prescribing information ↗
What the featured evidence can tell us
Ovarian suppression changes sex-hormone exposure and requires indication-specific clinical monitoring. The combination trial does not isolate the safety of triptorelin from other treatment components.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Identity, route, and evidence limits
The randomized contrast was between endocrine-treatment strategies. Because ovarian suppression had multiple methods, the outcome difference cannot be attributed to triptorelin alone.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Official product context · checked October 4, 2026
An early hormone increase can temporarily worsen symptoms. The medication reference also discusses metabolic changes and clinical monitoring during longer treatment.
Source: MedlinePlus · Triptorelin injection ↗
Regulatory status
- U.S. FDA approval
- Approved
Trelstar (NDA 020715, approved 2000) for advanced prostate cancer and Triptodur (NDA 208956, approved 2017) for central precocious puberty. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.1 Testosterone-stimulating peptides in males
Named explicitly as a GnRH agonist analogue ("triptorelin"); prohibited in males. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Medicine status & clinical context
Triptorelin is a prescription GnRH agonist with product-dependent uses in prostate cancer and central precocious puberty. The breast-cancer endocrine strategy summarized here is a separate study context and does not isolate the effect of triptorelin from all accompanying treatments.
The featured evidence concerns ovarian suppression alongside endocrine therapy in premenopausal hormone-receptor-positive early breast cancer. It is not a trial isolating triptorelin’s effect.
Source: MedlinePlus · Triptorelin injection ↗
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
How Triptorelin works
Sustained GnRH agonist exposure can suppress reproductive-hormone signaling. Its clinical effect differs from short-term or pulsatile stimulation of the same general pathway.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Molecular structure
Questions worth asking
- Can the benefit be attributed to triptorelin alone?
- What population, comparator, and route were actually studied?
- The randomized contrast was between endocrine-treatment strategies. Because ovarian suppression had multiple methods, the outcome difference cannot be attributed to triptorelin alone.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Can the benefit be attributed to triptorelin alone?
No. Both groups received ovarian suppression through different permitted methods. The randomized comparison concerned the accompanying endocrine therapies.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. · 2014 ↗
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
